Vancouver, BC Canada – Andira Pharmaceuticals is pleased to announce it has retained MCRA LLC, a world leading global medical device, regulatory and clinical research consulting firm based in Washington, DC, to consult and provide guidance during the regulatory approval process for its anti-microbial wound care adhesive which offers significantly
Vancouver, July 8, 2021– Andira Pharmaceuticals (“Andira”) has been awarded two consecutive Mitacs Accelerate Internship grants to advance anti-infective R&D within the Prof. Charles Thompson Laboratory at the University of British Columbia (UBC) Department of Microbiology and Immunology. Both Mitacs grants directly support Dr. Claudia Dietrich, a UBC research scientist,
Vancouver, July 7, 2021– Andira Pharmaceuticals today announces it has secured an exclusive worldwide license for a portfolio of three cannabinoid antibiotic technologies along with their complementary drug delivery systems designed to prevent and treat multi-drug resistant infections. The license was granted by the University of British Columbia (UBC). Inventors
Vancouver, British Columbia, Canada– Andira Pharmaceuticals welcomes to its board of directors, Dr. Ethan Russo, a global pioneer in the development of cannabinoid therapeutics. Andira is a privately-held biopharmaceutical firm dedicated to the advancement of cannabinoid-based therapeutics for infectious disease and oncology indications in the traditional pharmaceutical business model. Andira
Vancouver, British Columbia, Canada– To protect novel anti-infective formulations developed at The University of British Columbia (UBC) for the treatment of Enterococcus, including the multi-drug-resistant superbug VRE, a Patent Cooperation Treaty (PCT) application entitled “Antibiotic Cannabinoid-Terpene Formulations” was filed in May 2020. The International Search Report & Written Opinion (ISR/WO)
Vancouver, BC Canada – Andira Pharmaceuticals is pleased to announce it has retained MCRA LLC, a world leading global medical device, regulatory and clinical research consulting firm based in Washington, DC, to consult and provide guidance during the regulatory approval process for its anti-microbial wound care adhesive which offers significantly
Vancouver, July 8, 2021– Andira Pharmaceuticals (“Andira”) has been awarded two consecutive Mitacs Accelerate Internship grants to advance anti-infective R&D within the Prof. Charles Thompson Laboratory at the University of British Columbia (UBC) Department of Microbiology and Immunology. Both Mitacs grants directly support Dr. Claudia Dietrich, a UBC research scientist,
Vancouver, July 7, 2021– Andira Pharmaceuticals today announces it has secured an exclusive worldwide license for a portfolio of three cannabinoid antibiotic technologies along with their complementary drug delivery systems designed to prevent and treat multi-drug resistant infections. The license was granted by the University of British Columbia (UBC). Inventors
Vancouver, British Columbia, Canada– Andira Pharmaceuticals welcomes to its board of directors, Dr. Ethan Russo, a global pioneer in the development of cannabinoid therapeutics. Andira is a privately-held biopharmaceutical firm dedicated to the advancement of cannabinoid-based therapeutics for infectious disease and oncology indications in the traditional pharmaceutical business model. Andira
Vancouver, British Columbia, Canada– To protect novel anti-infective formulations developed at The University of British Columbia (UBC) for the treatment of Enterococcus, including the multi-drug-resistant superbug VRE, a Patent Cooperation Treaty (PCT) application entitled “Antibiotic Cannabinoid-Terpene Formulations” was filed in May 2020. The International Search Report & Written Opinion (ISR/WO)
For media, investors room, further information or other inquiries, please contact us here:
Subscribe to our mailing list to receive Andira news releases.
Copyright © 2024 Andira Pharmaceuticals
